Screener
Agios Pharmaceuticals AGIO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $16,345 | $18,355 |
| Accrued expenses | 34,647 | 45,459 |
| Operating lease liabilities | 19,225 | 18,392 |
| Total current liabilities | 70,217 | 82,206 |
| Operating lease liabilities, net of current portion | 11,946 | 21,815 |
| Other non-current liabilities | 240 | 90 |
| Total liabilities | 82,403 | 104,111 |
| Stockholders’ equity: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's total current liabilities?
- Agios Pharmaceuticals (AGIO) reported total current liabilities of $70.22M in Q2 2026.
- How has Agios Pharmaceuticals's total current liabilities changed year-over-year?
- Agios Pharmaceuticals's total current liabilities decreased by 0.3% year-over-year, from $70.41M to $70.22M.
- What is the long-term trend for Agios Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's total current liabilities has grown at a -2.7% compound annual growth rate (CAGR), from $94.39M to $82.21M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Agios Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude